KRYS
Krystal Biotech, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +9.1% ·
share flow +1.0% ·
net new positions +8.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 6.57K | $2.18M | n/a | n/a |
| Q2 2026 | 109 | +2 | 18.97M | $7.05B | +12 | −9 |
| Q1 2026 | 109 | 0 | 17.81M | $4.60B | +7 | −8 |
| Q4 2025 | 109 | +2 | 19.84M | $4.89B | +3 | n/a |
| Q3 2025 | 18 | +1 | 16.09M | $2.84B | +2 | −2 |
| Q2 2025 | 15 | -1 | 14.75M | $2.03B | n/a | −1 |
| Q1 2025 | 13 | +1 | 3.64M | $657.03M | +1 | n/a |
| Q4 2024 | 12 | +1 | 3.56M | $557.49M | +1 | n/a |
| Q3 2024 | 10 | +2 | 2.25M | $408.78M | +2 | n/a |
| Q2 2024 | 8 | n/a | 2.10M | $386.05M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 1.28M | n/a | $200.36M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Capital World Investors ✦ | 879.20K | 0.0% | $137.74M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 591.60K | 0.0% | $92.70M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | T. Rowe Price ✦ | 509.46K | +16.2% | $79.81M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 219.53K | -10.1% | $34.39M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Millennium Management ✦ | 18.96K | -60.2% | $2.97M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 11.70K | -7.7% | $1.83M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 8 | Citadel Advisors ✦ | 11.02K | +11374.0% | $1.73M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 10.90K | -24.3% | $1.71M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Marshall Wace ✦ | 10.33K | New | $1.62M | 0.0% | New | 1 | SEC ↗ ×2 |
| 11 | AQR Capital Management ✦ | 9.34K | +11.8% | $1.46M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 12 | D. E. Shaw & Co. ✦ | 7.43K | -20.5% | $1.16M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $1.62M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 364 holders, 28.19M shares, $7.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director, 10% owner · 399 sh · $146,256
Officer, Director, 10% owner · 3.96K sh · $1.42M
Officer, Director, 10% owner · 3.18K sh · $1.14M
Officer, Director, 10% owner · 3.39K sh · $1.22M
Officer, Director, 10% owner · 2.32K sh · $836,281
Officer, Director, 10% owner · 1.24K sh · $449,120
Officer, Director, 10% owner · 1.99K sh · $722,404
Officer, Director, 10% owner · 565 sh · $205,287
Officer, Director, 10% owner · 1.33K sh · $484,390
Officer, Director, 10% owner · 826 sh · $301,832
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology